Instrument Inactif

Communiqués Lightlake Therapeutics OTC Bulletin Board

Actions

US53224T1051

Recherche biotechnologique et médicale

Cours en clôture OTC Bulletin Board
- ^USD	-

02/03/23	Indivior complète l'acquisition d'Opiant Pharmaceuticals	AN
02/03/23	Indivior conclut l'accord d'achat d'Opiant Pharmaceuticals	MT

Communiqués

02/03/23	OPIANT PHARMACEUTICALS, INC. : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	AQ
01/03/23	OPIANT PHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)	AQ
27/02/23	OPIANT PHARMACEUTICALS, INC. : Change in Directors or Principal Officers (form 8-K)	AQ
07/02/23	OPIANT PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
07/02/23	Opiant Pharmaceuticals Announces CFIUS Approval for Proposed Acquisition by Indivior PLC	GL
06/02/23	Opiant Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition by Indivior PLC	GL
19/01/23	Opiant Pharmaceuticals Announces FDA Acceptance and Priority Review of NDA for OPNT003, Nasal Nalmefene, for Opioid Overdose	GL
09/01/23	OPIANT PHARMACEUTICALS, INC. : Change in Directors or Principal Officers (form 8-K)	AQ
07/01/23	OPIANT PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Opiant Pharmaceuticals, Inc. - OPNT	BU
22/11/22	Opiant Pharmaceuticals Announces Completion of Rolling NDA Submission for OPNT003, Nasal Nalmefene, for Opioid Overdose	AQ
15/11/22	OPIANT PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits (form 8-K)	AQ
15/11/22	OPIANT PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Opiant Pharmaceuticals, Inc. - OPNT	BU
14/11/22	OPIANT PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operation (form 10-Q)	AQ
14/11/22	OPNT Alert: Monsey Firm of Wohl & Fruchter LLP Investigating Sale of Opiant Pharmaceuticals	AQ
14/11/22	Opiant Pharmaceuticals Announces Third Quarter 2022 Financial Results	AQ
14/11/22	Indivior To Acquire Opiant Pharmaceuticals	PR
27/10/22	Opiant Pharmaceuticals to Report Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 14, 2022	AQ
06/10/22	Opiant Pharmaceuticals Announces Completion of Enrollment in Phase 2 Clinical Trial of OPNT002, Nasal Naltrexone, in Patients with Alcohol Use Disorder	AQ
22/08/22	Opiant Pharmaceuticals Announces Notice of Allowance for U.S. Patent with Claims Covering OPNT004 for the Treatment of Cannabinoid Hyperemesis Syndrome	AQ
12/08/22	MindMed Strengthens Board with Appointment of Two New Independent Directors	PR
11/08/22	Opiant Pharmaceuticals : Announces Second Quarter and First Half 2022 Financial Results and Provides Corporate Update - Form 8-K	PU
11/08/22	OPIANT PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operation (form 10-Q)	AQ
11/08/22	Opiant Pharmaceuticals Announces Second Quarter and First Half 2022 Financial Results and Provides Corporate Update	AQ
08/08/22	Opiant Pharmaceuticals Announces Additional $2.1 Million Funding Under BARDA Contract for OPNT003, Nasal Nalmefene	AQ
02/08/22	Opiant Pharmaceuticals Announces Notice of Allowance for U.S. Patent With Claims Covering OPNT003 for the Treatment of Opioid Overdose	AQ